Mounjaro Price 2026: Cost Without Insurance and Savings
What Mounjaro costs you in September 2026 at list price, through LillyDirect, with Lilly's savings card and on Medicare, and how it relates to Zepbound, the tirzepatide product approved for weight management.
Mounjaro has a list price of $1,112.16 per fill, which Lilly defines as a month's supply of four pens, and through LillyDirect every dose from 2.5 mg to 15 mg starts at $499 a month self-pay. Before you compare prices, know what it is approved for: Mounjaro is FDA-approved for type 2 diabetes only, not for weight loss. Lilly lists its uses as improving blood sugar in adults and children 10 and older with type 2 diabetes, and reducing the risk of major cardiovascular events such as heart attack, stroke or cardiovascular death in adults with type 2 diabetes who are at high risk for them. Zepbound is the tirzepatide product approved for weight management. It has the same active ingredient, tirzepatide, under a different approved indication, and its prices are in our Zepbound cost guide. If your commercial plan covers Mounjaro, Lilly's savings card can bring a 1, 2 or 3-month fill as low as $25 until the card expires on December 31, 2026. Every price on this page is as of September 11, 2026.
Average Costs Comparison
These are Lilly's channels and the government ones, with what each charges for a month of Mounjaro. Lilly counts a month as four single-dose pens, and the savings card defines it as 28 days. Telehealth prices for brand Mounjaro are not shown here.
| Provider | Monthly Cost | Per Dose | Consultation | Shipping | Notes |
|---|---|---|---|---|---|
| Pharmacy at list price | $1,112.16 per fill (list price) | 4 single-dose pens per month | Prescription required | Pharmacy pickup | Lilly's list price, WAC from AnalySource accessed January 1, 2026. Lilly says what you pay at the pharmacy may differ, depending on your insurance, pharmacy charges and any discounts |
| LillyDirect self-pay | Starting at $499/month at every dose, 2.5 mg to 15 mg | 4 single-dose pens per month | Prescription for an approved use required | Free delivery or pickup | Filled by Amazon Pharmacy, Fuze Health, Gifthealth or Walmart Pharmacy at one price. FSA/HSA eligible, though eligibility may vary by plan. Additional taxes and fees may apply |
| Savings card, your plan covers Mounjaro | As little as $25 per 1, 2 or 3-month fill | Up to 4, 8 or 12 pens (28, 56 or 84 days) | Your plan's usual visit cost | Your pharmacy | Savings capped at $150, $300 or $450 per 1, 2 or 3-month fill and $1,950 per calendar year; up to 13 fills a year; card expires December 31, 2026 |
| Savings card, your plan does not cover Mounjaro | As low as $499 for a 1-month fill | Up to 4 pens (28 days) | Your plan's usual visit cost | Your pharmacy | Requires commercial drug insurance. Savings capped at $647 a month and $8,411 per calendar year; up to 13 fills a year; card expires December 31, 2026 |
| Medicare Part D | Set by your Part D plan | Per your plan | Your plan's usual visit cost | Your pharmacy | Mounjaro is not on the Medicare GLP-1 Bridge list. Medicare.gov says your drug plan should cover GLP-1 medications for type 2 diabetes. Lilly's savings card is not available on Medicare |
| TrumpRx listing | 55% off an Original Price of $1,112.16 | Single-dose pen, 2.5 mg to 15 mg | Prescription required | Delivery through LillyDirect | TrumpRx hands you to LillyDirect, which guides you through savings options and offers delivery. You cannot buy drugs directly from TrumpRx |
Top Weight Loss Providers by Value
GLP-1 Weight Loss From $179/mo - Free 2-Minute Assessment
- Compounded GLP-1 (semaglutide) from $179/mo, GLP-1 + GIP (tirzepatide) from $259/mo
- Brand-name Ozempic®, Mounjaro®, Zepbound® and Wegovy® also available
- Free 2-minute qualification quiz and FREE doctor consultation - no cost, no obligation
- Free tracked shipping straight to your door after approval
First Month $179, Then $299/mo With No Membership Fee
- Doctor-guided GLP-1 care, 100% online - no waiting rooms
- Free dietician visits and care coaching included with your plan
- Doctor-formulated plans adjusted as your body responds
- Fast, discreet shipping to your door
Wegovy® From $149/mo Plus Membership From $74/mo - Free Insurance Check
- Full GLP-1 suite: Zepbound®, Wegovy® pill and pen, semaglutide and more
- Free insurance check shows what your plan covers before you pay
- Tirzepatide (Zepbound®) averaged up to 20.9% body weight loss in the 72-week SURMOUNT-1 trial; individual results vary
- On-demand provider coaching and support, 100% online
What You Pay, by Coverage Situation
No insurance
LillyDirect lists every Mounjaro dose at "Starting at $499/month" for self-pay, with free delivery or pickup. Four dispensing pharmacies fill LillyDirect orders (Amazon Pharmacy, Fuze Health, Gifthealth and Walmart Pharmacy), and Lilly says you pay one price whichever of them fills yours. You need a prescription, and the LillyDirect purchase terms ask you to confirm it is for an approved use consistent with the FDA-approved labeling, which for Mounjaro means type 2 diabetes. The LillyDirect terms also require you to be 18 or older and a resident of the US or Puerto Rico.
Commercial plan that covers Mounjaro
Lilly's savings card can bring your cost as low as $25, on a 1-month, 2-month or 3-month fill. Lilly counts a month as 28 days and up to 4 pens, and the card allows up to 13 fills per calendar year (13 fills of 28 days is 364 days). Savings are capped at $150 per 1-month fill, $300 per 2-month fill and $450 per 3-month fill, with a separate $1,950 annual cap, and anything above those caps is yours to pay. The card expires and savings end on December 31, 2026.
Commercial plan that does not cover Mounjaro
If you have commercial drug insurance but your plan does not cover Mounjaro, the card lets you pay as low as $499 for a 1-month fill, with savings capped at $647 a month and $8,411 per calendar year. That matches the LillyDirect self-pay starting price, so compare both routes before you choose where to fill. If your plan runs an alternate funding program tied to manufacturer copay help, Lilly says you cannot use the card at all.
Medicare, Medicaid, VA or TRICARE
Lilly's savings card excludes Medicaid, Medicare, Medigap, DoD, VA, TRICARE/CHAMPUS and state assistance programs. On Medicare Part D, your plan sets your Mounjaro cost, and medicare.gov says your drug plan should cover GLP-1 medications for type 2 diabetes. Mounjaro is not one of the drugs in the Medicare GLP-1 Bridge, and having type 2 diabetes makes you ineligible for the Bridge. Lilly's savings page describes the Medicare Prescription Payment Plan as a free budgeting tool that can help you manage prescription costs with fixed monthly payments over the plan year. If a government plan does not cover Mounjaro, Lilly says you may be eligible for self-pay options, but a LillyDirect self-pay purchase does not count toward your Part D true out-of-pocket costs.
Zepbound: the tirzepatide approved for weight management
Mounjaro is approved for adults and children 10 and older with type 2 diabetes, so a prescription for weight loss would be off-label, and Lilly's savings card and LillyDirect terms both require a prescription for an approved use. Zepbound is Lilly's tirzepatide for weight management: the same active ingredient, tirzepatide, under a different approved indication. On LillyDirect, Zepbound self-pay starts at $299 a month, and the dose-by-dose prices are in our Zepbound cost guide.
Does Insurance Cover Mounjaro?
Lilly says what you pay will largely depend on your prescription drug insurance plan, and that data on specific plan pricing is not yet available. Both of Lilly's price programs are tied to Mounjaro's approval: the savings card and LillyDirect self-pay each require a prescription for an approved use consistent with the FDA-approved labeling, and Mounjaro is FDA-approved for type 2 diabetes only.
Commercial insurance that covers Mounjaro
Coverage: As little as $25 per 1, 2 or 3-month fill with the savings card
Card savings are capped at $150, $300 or $450 per fill and $1,950 per calendar year, for up to 13 fills, and the card ends December 31, 2026.
Commercial insurance that does not cover Mounjaro
Coverage: As low as $499 per 1-month fill with the savings card
Savings are capped at $647 a month and $8,411 a year. The card is off limits if your plan uses an alternate funding program tied to manufacturer copay help.
Medicare Part D
Coverage: Your plan sets the price
Medicare.gov says your drug plan should cover GLP-1 medications for type 2 diabetes. Mounjaro is not in the Medicare GLP-1 Bridge, which covers Foundayo, Wegovy and the Zepbound KwikPen for a $50 monthly copay, and type 2 diabetes makes you ineligible for the Bridge. Medicare says its Prescription Payment Plan spreads your out-of-pocket drug costs across the calendar year.
Medicaid, VA, TRICARE and state programs
Coverage: Lilly savings card not available
Lilly says you can call Lilly Support Services or the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979) for information on other types of affordability solutions.
Is There a Generic Mounjaro?
No. Drugs@FDA (openFDA data updated September 11, 2026) lists only two tirzepatide applications, both held by Eli Lilly: Mounjaro, first approved May 13, 2022, and Zepbound, first approved November 8, 2023. No generic tirzepatide application appears. Zepbound is a separate Lilly product with its own price list. Compounded tirzepatide is compounded, not FDA-approved: the FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed, and as of May 31, 2026 it had received more than 730 adverse event reports tied to compounded, not FDA-approved tirzepatide.
| Medication | Compounded/Generic | Brand-Name | Savings |
|---|---|---|---|
| Mounjaro (tirzepatide), type 2 diabetes | No generic application in Drugs@FDA | $1,112.16 list; from $499/month on LillyDirect | As little as $25 per fill with covered commercial insurance |
| Zepbound (tirzepatide), weight management | No generic application in Drugs@FDA | Self-pay starting at $299/month on LillyDirect | Full prices in the Zepbound cost guide |
| Compounded tirzepatide (compounded, not FDA-approved) | Not reviewed by the FDA for safety, effectiveness or quality | Not a Lilly product | No compounded price is quoted in this guide |
Ways to Lower Your Mounjaro Bill
- With coverage, ask your prescriber whether a 3-month prescription makes sense. Lilly says you may pay as little as $25 in total for a 3-month fill (84 days, up to 12 pens) with the savings card.
- Mark December 31, 2026 on your calendar. That is when the Mounjaro savings card expires and its savings end.
- Paying without insurance? LillyDirect charges one price whichever of its four pharmacies fills your order, so there is nothing to gain by shopping among them.
- If you have an FSA or HSA, Lilly says LillyDirect purchases are eligible, though eligibility may vary by plan.
- If your commercial plan does not cover Mounjaro, the savings card price of $499 and the LillyDirect starting price of $499 are the two to compare, and both can carry taxes or fees.
- On Medicare, ask about the Medicare Prescription Payment Plan. Medicare says it spreads your out-of-pocket drug costs across the calendar year.
- If you are pricing Mounjaro because you want to lose weight, ask your prescriber about Zepbound instead. Mounjaro is approved only for adults and children 10 and older with type 2 diabetes, so using it for weight loss is off-label, and Lilly's savings programs require an approved use.
- For other affordability options, Lilly Support Services and the Lilly Answers Center take calls at 1-800-LillyRx (1-800-545-5979).
Charges and Limits in the Fine Print
- LillyDirect self-pay: Lilly says additional taxes and fees may apply on top of the $499 starting price.
- Savings card: you are responsible for any applicable taxes, fees and any amount above the card's maximums ($150 per 1-month fill and $1,950 a year with coverage; $647 a month and $8,411 a year without coverage), and the card covers at most 13 fills per calendar year.
- Self-pay purchases do not count toward your insurance deductible or out-of-pocket spending, and on Medicare Part D they do not count toward your true out-of-pocket (TrOOP) costs.
- Alternate funding programs: if your plan uses one, Lilly says you are not eligible for and cannot use the savings card.
- The savings card expires and its savings end on December 31, 2026.
Frequently Asked Questions
How much does Mounjaro cost without insurance?
Starting at $499 a month at any dose through LillyDirect, Lilly's self-pay pharmacy service, with free delivery or pickup. At a pharmacy, the list price is $1,112.16 per fill of four pens. Mounjaro is FDA-approved for type 2 diabetes only, and LillyDirect requires a prescription for an approved use. Prices are as of September 11, 2026.
Is Mounjaro FDA-approved for weight loss?
No. Mounjaro is FDA-approved for type 2 diabetes only: to improve blood sugar in adults and children 10 and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them. Zepbound is the tirzepatide product approved for weight management.
What is the difference between Mounjaro and Zepbound?
Zepbound has the same active ingredient, tirzepatide, under a different approved indication. Mounjaro is approved for type 2 diabetes only, Zepbound is approved for weight management, and each has its own Lilly price list: Mounjaro self-pay starts at $499 a month on LillyDirect and Zepbound self-pay starts at $299. Drugs@FDA lists them as two separate Eli Lilly applications.
How much is Mounjaro with insurance?
As little as $25 for a 1, 2 or 3-month fill if your commercial plan covers Mounjaro and you use Lilly's savings card. Savings are capped at $150, $300 or $450 per fill and $1,950 per calendar year, and the card expires December 31, 2026. If your commercial plan does not cover it, the card brings a 1-month fill as low as $499.
Does Medicare cover Mounjaro?
Your Medicare Part D plan is the route. Mounjaro is FDA-approved for type 2 diabetes only, and medicare.gov says your Medicare drug plan should cover GLP-1 medications for type 2 diabetes, at a cost your plan sets. Mounjaro is not part of the $50 Medicare GLP-1 Bridge, which covers Foundayo, Wegovy and the Zepbound KwikPen, and having type 2 diabetes makes you ineligible for the Bridge. Lilly's savings card is not available on Medicare.
Is there a generic Mounjaro?
No. Drugs@FDA (openFDA data updated September 11, 2026) lists no generic tirzepatide application; the only two tirzepatide applications are Lilly's Mounjaro and Zepbound. Compounded tirzepatide is compounded, not FDA-approved, and is a different product from Mounjaro.
Can I use the Mounjaro savings card for weight loss?
Not if weight loss is the reason for your prescription. The card requires a prescription for an approved use consistent with the FDA-approved labeling, and Mounjaro is approved for type 2 diabetes only, in adults and children 10 and older, so a weight-loss prescription is off-label. LillyDirect self-pay has the same approved-use requirement. For weight management, ask your prescriber about Zepbound, which has its own Lilly savings options.
Does the Mounjaro price go up with the dose?
Not on LillyDirect. Every dose from 2.5 mg to 15 mg is listed at "Starting at $499/month" for self-pay. The $1,112.16 list price is also quoted per fill, not per dose.
Is compounded tirzepatide a cheaper Mounjaro?
No. Compounded tirzepatide is compounded, not FDA-approved, so it is not a version of Mounjaro at any price. The FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed, and it had received more than 730 adverse event reports tied to compounded, not FDA-approved tirzepatide as of May 31, 2026.
Sources & References
Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.
- FDA Drug InformationGLP-1 medication approvals and safety
- NIH National Institute of DiabetesWeight management research
- CDC Obesity InformationObesity statistics and health impacts
- Obesity Medicine AssociationClinical obesity treatment guidelines
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
Start With a Top Weight Loss Provider
GLP-1 Weight Loss From $179/mo - Free 2-Minute Assessment
- Compounded GLP-1 (semaglutide) from $179/mo, GLP-1 + GIP (tirzepatide) from $259/mo
- Brand-name Ozempic®, Mounjaro®, Zepbound® and Wegovy® also available
- Free 2-minute qualification quiz and FREE doctor consultation - no cost, no obligation
- Free tracked shipping straight to your door after approval
First Month $179, Then $299/mo With No Membership Fee
- Doctor-guided GLP-1 care, 100% online - no waiting rooms
- Free dietician visits and care coaching included with your plan
- Doctor-formulated plans adjusted as your body responds
- Fast, discreet shipping to your door
Wegovy® From $149/mo Plus Membership From $74/mo - Free Insurance Check
- Full GLP-1 suite: Zepbound®, Wegovy® pill and pen, semaglutide and more
- Free insurance check shows what your plan covers before you pay
- Tirzepatide (Zepbound®) averaged up to 20.9% body weight loss in the 72-week SURMOUNT-1 trial; individual results vary
- On-demand provider coaching and support, 100% online
Ready to Compare Providers?
Use our cost calculator to get personalized pricing estimates based on your insurance and location.
Disclaimer: Pricing information is based on publicly available data and may change without notice. Actual costs depend on your specific treatment plan, insurance coverage, and provider. Always verify current pricing with providers before purchasing. This article is for informational purposes only and is not financial or medical advice. We may receive compensation through affiliate links, which helps support our research.
Regulatory noticeRegulatory note (verified August 22, 2026): On February 20, 2026 the FDA issued MEDVi, LLC a warning letter (MARCS-CMS 721455) citing misbranding under sections 502(a) and 502(bb) of the FD&C Act. Reviewing medvi.io in December 2025, the FDA said labels bearing "MEDVi" implied MEDVi compounds the drugs when it does not, and that "Same active ingredient as Wegovy and Ozempic" and "Same active ingredient as Mounjaro and Zepbound" implied an FDA approval compounded drugs do not have. We found no close-out letter, so the matter appears open. MEDVi states medvi.io is affiliate-operated rather than company-operated; we could not verify that, and the letter is addressed to MEDVi, LLC. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. Three site claims are also quoted, among them "Generic Zepbound, Mounjaro" and "Semaglutide is the active ingredient in the brand medications." Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. FDA’s warning letter index shows no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): Eden Health International Inc. was sent FDA warning letter MARCS-CMS 728279 on June 8, 2026, following an agency review of tryeden.com in March 2026. The letter lists two findings. The first is the "Eden" name on pictured labels for compounded semaglutide and tirzepatide, which the FDA said represents Eden as the compounder when it is not. The second is the site’s description of its sourcing as "FDA-licensed 503(a) outsourcing facilities," a designation the agency says does not exist, because the FD&C Act creates no FDA approval or license for pharmacies or outsourcing facilities. Both were cited as misbranding under sections 502(a) and 502(bb). FDA has posted no close-out letter, so the matter reads as open. Read the FDA letter
Verification limitationVerification note (checked August 23, 2026): we could not identify the legal entity behind HealthRx through public records. Its website does not name an operating company, its domain registration is privacy-shielded, and we could not confirm a listing in any business registry or accreditation database we checked. This is not a finding of wrongdoing. It means our usual checks, including our search of FDA enforcement records, could only be run against the brand name and domain rather than a confirmed company.
Regulatory noticeRegulatory note (verified August 22, 2026): One sentence is all that FDA warning letter MARCS-CMS 715879 quotes. Sent to Sprout Health Partners LLC on September 9, 2025 after an August 2025 review of joinsprouthealth.com, it cites the line "GLP-1 medications are FDA-approved and backed by extensive clinical research..." Appearing on pages offering compounded semaglutide and tirzepatide, that statement implied to the agency that the compounded products themselves are FDA-approved, which they are not, and it was cited as misbranding under FD&C Act 502(a) and 502(bb). A search of FDA’s warning letter index turns up no close-out letter, so the matter appears open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): Skinny.Rx operates as SkinnyRx, but the legal entity is Lean Rx, Inc., and that is the name on FDA warning letter MARCS-CMS 717989, dated February 20, 2026. Following a December 2025 review of skinnyrx.com, the agency objected to the "SkinnyRx" name on pictured labels, saying it implies SkinnyRx compounds the drugs itself, and to three marketing lines, including "Get access to the same active ingredient as name-brand GLP-1 medications" and "It contains the same active ingredient as FDA-approved medications." Compounded semaglutide and tirzepatide are not FDA-approved, so the FDA read those lines as implying an approval that does not exist and classed the products as misbranded. No close-out letter is posted; read the matter as unresolved. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): Hers is a brand of Hims & Hers Health, Inc., and the FDA wrote to that company twice on September 9, 2025, once for each brand. The Hers letter, MARCS-CMS 716825, went to chief executive Andrew Dudum after an August 2025 review of forhers.com. It quotes two claims made for compounded semaglutide: "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." The agency’s position is that compounded products carry no FDA approval, so claims like these imply a sameness with approved medicines that has not been established, making the products misbranded. FDA’s index lists neither a response nor a close-out letter, so the matter stands open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. Two lines about compounded semaglutide are quoted in it: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." Compounded drug products are not FDA-approved, and the agency said phrasing of this sort suggests otherwise, which is what makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. No close-out letter appears in FDA’s index; treat this as open. Read the FDA letter